STOCK TITAN

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

LENZ Therapeutics, Inc. will announce its first quarter 2024 financial results and business update on May 8, 2024. The company focuses on developing aceclidine-based eye drops for presbyopia. A webcast will be held to discuss the results and updates.

LENZ Therapeutics, Inc. annuncerà i risultati finanziari del primo trimestre del 2024 e gli aggiornamenti aziendali l'8 maggio 2024. La compagnia si concentra sullo sviluppo di colliri a base di aceclidina per la presbiopia. Sarà organizzato un webcast per discutere i risultati e gli aggiornamenti.
LENZ Therapeutics, Inc. anunciará los resultados financieros del primer trimestre de 2024 y las actualizaciones empresariales el 8 de mayo de 2024. La empresa se enfoca en el desarrollo de gotas oftálmicas a base de aceclidina para la presbicia. Se realizará una transmisión en línea para discutir los resultados y las actualizaciones.
LENZ Therapeutics, Inc.는 2024년 첫 분기 재무 결과와 비즈니스 업데이트를 2024년 5월 8일에 발표할 예정입니다. 이 회사는 노안을 위한 아셀리딘 기반 안약 개발에 중점을 둡니다. 결과 및 업데이트에 대해 논의하기 위해 웹캐스트가 열릴 예정입니다.
LENZ Therapeutics, Inc. annoncera ses résultats financiers pour le premier trimestre 2024 et les mises à jour de l'entreprise le 8 mai 2024. La société se concentre sur le développement de gouttes oculaires à base d'acéclidine pour la presbytie. Un webcast sera organisé pour discuter des résultats et des mises à jour.
LENZ Therapeutics, Inc. wird am 8. Mai 2024 die Finanzergebnisse des ersten Quartals 2024 und Geschäftsaktualisierungen bekannt geben. Das Unternehmen konzentriert sich auf die Entwicklung von Aceclidin-basierten Augentropfen für Presbyopie. Eine Webübertragung wird abgehalten, um die Ergebnisse und Updates zu diskutieren.
Positive
  • None.
Negative
  • None.

SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 8, 2024 at 4:30 p.m. ET to report its first quarter 2024 financial results and provide a business update.

The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.

About LENZ Therapeutics
LENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on the development and commercialization of the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. LENZ’s product candidates, LNZ100 is a preservative-free, single-use, once-daily eye drops containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY trials as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day.” LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.

Contacts:

Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com

Janhavi Mohite
Stern Investor Relations, Inc.
janhavi.mohite@sternir.com


FAQ

When will LENZ Therapeutics report its first quarter financial results?

LENZ Therapeutics will report its first quarter financial results on May 8, 2024.

What is LENZ Therapeutics focused on developing?

LENZ Therapeutics is focused on developing the first aceclidine-based eye drop for presbyopia.

Where can the webcast be accessed?

The webcast can be accessed on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section.

How long will the webcast replay be available?

The webcast replay will be available on the Company's website for 30 days following the event.
LENZ THERAPEUTICS INC

NASDAQ:LENZ

LENZ Rankings

LENZ Latest News

LENZ Stock Data

585.70M
26.77M
2.82%
90.5%
9.27%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOLANA BEACH